Alice Castaldo

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

The Role of ETI Therapy in Managing Sinusitis in Cystic Fibrosis pediatric population: A Study on Clinical Outcomes.

The Role of ETI Therapy in Managing Sinusitis in Cystic Fibrosis pediatric population: A Study on Clinical Outcomes.

Journal: Respiratory medicine

Published: January 16, 2026

Red blood cell deformability as a mechanobiological marker of CFTR dysfunction in cystic fibrosis.

Red blood cell deformability as a mechanobiological marker of CFTR dysfunction in cystic fibrosis.

Journal: iScience

Published: December 03, 2025

Unusual Onset of Hereditary Hemorrhagic Telangiectasia Due to Somatic Mutational Mosaicism: Case Report and Review of the Literature.

Unusual Onset of Hereditary Hemorrhagic Telangiectasia Due to Somatic Mutational Mosaicism: Case Report and Review of the Literature.

Journal: Children (Basel, Switzerland)

Published: October 30, 2025

Elexacaftor/Tezacaftor/Ivacaftor Therapy in a Child With Cystic Fibrosis and Type 1 Spinal Muscular Atrophy.

Elexacaftor/Tezacaftor/Ivacaftor Therapy in a Child With Cystic Fibrosis and Type 1 Spinal Muscular Atrophy.

Journal: Pediatric pulmonology

Published: October 07, 2025

Pulmonary Function Modulates Epigenetic Age in Subjects with Cystic Fibrosis.

Pulmonary Function Modulates Epigenetic Age in Subjects with Cystic Fibrosis.

Journal: International journal of molecular sciences

Published: June 04, 2025

Exploring the role of β2- and β3-adrenergic receptors in cystic fibrosis.

Exploring the role of β2- and β3-adrenergic receptors in cystic fibrosis.

Journal: Pulmonary pharmacology & therapeutics

Published: May 07, 2025

Sex-based immunological differences in multisystem inflammatory syndrome in children: potential role of TR3-56 cells for pathogenesis, diagnosis, and therapy.

Sex-based immunological differences in multisystem inflammatory syndrome in children: potential role of TR3-56 cells for pathogenesis, diagnosis, and therapy.

Journal: Frontiers in immunology

Published: April 04, 2025

Hemoglobin Levels in Children Treated for Cystic Fibrosis with CFTR Modulators: A Single Center Retrospective Study.

Hemoglobin Levels in Children Treated for Cystic Fibrosis with CFTR Modulators: A Single Center Retrospective Study.

Journal: Journal of clinical medicine

Published: March 08, 2025

Blood platelet reduction after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction.

Blood platelet reduction after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction.

Journal: Scientific reports

Published: February 24, 2025

How Effectively Can Oxidative Stress and Inflammation Be Reversed When CFTR Function Is Pharmacologically Improved?

How Effectively Can Oxidative Stress and Inflammation Be Reversed When CFTR Function Is Pharmacologically Improved?

Journal: Antioxidants (Basel, Switzerland)

Published: January 27, 2025

TAS2R38 genotype and CRS severity in children with cystic fibrosis.

TAS2R38 genotype and CRS severity in children with cystic fibrosis.

Journal: Heliyon

Published: December 31, 2024

Tracheal Diverticula in People with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: An Italian Multicenter Retrospective Study.

Tracheal Diverticula in People with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: An Italian Multicenter Retrospective Study.

Journal: Journal of clinical medicine

Published: November 27, 2024

Showing 1-12 of 47

Last Updated: 09/26/2026